Automated Compounding Device (Oncology) Market

Market Overview The Global Automated Compounding Device (Oncology) Market is projected to expand from USD 338.26 Million in 2025 to USD 541.87 Million by 2031, achieving a compound annual growth rate of 8.17%. These specialized robotic systems are engineered to prepare hazardous chemotherapy medications with high precision, thereby minimizing human contact with toxic substances. The market's growth is primarily fueled by the critical necessity to improve medication safety by mitigating compounding errors and the rising global prevalence of cancer, which requires increased volumes of chemotherapy preparations. As reported by the American Society of Health-System Pharmacists in 2024, technologies assisting in sterile product preparation were employed in 62.8% of hospitals, highlighting the growing reliance on automation to ensure accuracy and compliance in handling hazardous drugs. Despite the evident safety advantages, the market's expansion encounters a major obstacle due to the significant capital investment needed for these sophisticated systems. The high upfront costs of acquisition and implementation, along with the ongoing expenses for maintenance and staff training, frequently discourage smaller healthcare facilities from adopting this technology. Consequently, budgetary constraints persist as a primary barrier that prevents widespread deployment across all levels of healthcare providers. Market Driver The escalating global prevalence of cancer and the resulting surge in demand for chemotherapy act as the main catalysts for the adoption of automated compounding devices in oncology. As patient numbers rise, hospital pharmacies face increasing pressure to generate sterile chemotherapy preparations at a scale that manual processes cannot sustainably support. Automation resolves this volume challenge by drastically boosting throughput while upholding the strict sterility standards necessary for immunocompromised patients. This urgency is underscored by the growing disease burden; the American Cancer Society's 'Cancer Facts & Figures 2025' report from January 2025 projected that over 2,041,000 new cancer cases would be diagnosed in the United States that year, indicating a critical trajectory where manual compounding methods will fail to meet expanding clinical needs. Concurrently, a stronger emphasis on occupational safety and exposure reduction is driving healthcare facilities to transition toward robotic systems. Handling hazardous antineoplastic drugs presents severe health risks to pharmacy staff, including potential mutagenic and carcinogenic effects from prolonged exposure. Regulatory bodies are reacting with stricter guidelines that require containment strategies, which are often best realized through automation. According to the National Institute for Occupational Safety and Health's December 2024 'List of Hazardous Drugs in Healthcare Settings, 2024', 25 new drugs were added to the hazardous category, reinforcing the broadening scope of substances requiring strict containment. This shift toward technology is further evidenced by wider industry trends; an article in Pharmacy Times from September 2025 titled 'Intelligent Pharmacy' noted that nearly 50% of global healthcare organizations intended to incorporate AI-driven automation into their workflows by the end of the year. Market Challenge The considerable capital investment necessary for automated compounding devices serves as a major restraint on market expansion, specifically for smaller healthcare institutions. Procurement entails not only the high purchase price of the robotic systems but also extensive costs related to facility modifications, software integration, and specialized personnel training. These financial demands create a barrier for community hospitals and rural centers operating on restricted budgets, preventing them from transitioning away from manual chemotherapy preparation. As a result, the market remains heavily concentrated within large academic research centers, limiting broader commercial penetration. This economic obstacle is evident in adoption metrics across major healthcare regions. As stated by the European Association of Hospital Pharmacists in 2024, fewer than 30% of hospital pharmacies in Europe had fully or partially adopted automation technologies. This statistic demonstrates that, despite the critical need for safety in oncology compounding, the financial burden of these technologies stifles widespread implementation. Consequently, the market struggles to capture volume in lower-tier segments, directly hampering the overall growth of the industry. Market Trends The transition toward gravimetric verification technologies marks a fundamental evolution in safety, moving beyond visual volumetric methods. This trend is gaining traction as facilities recognize that weight-based verification provides a precise method to ensure the concentration of oncology ingredients. Scale-based checks detect deviations that manual methods miss, significantly mitigating dosing errors. However, adoption remains early due to operational complexity; according to the 'Is IVWMS Adoption Rate Fast Enough?' article in Pharmacy Practice News from December 2024, gravimetrics to verify dose, amount, and volume was utilized by only 7.7% of hospital pharmacies overall in 2023. Additionally, the rise of personalized medicine and genomic-based dosing is reshaping the market by demanding higher precision for patient-specific chemotherapy. Treatments now rely on biomarker-driven therapies requiring exact dosages tailored to an individual’s genetic profile, necessitating the accuracy that only robotic systems can consistently deliver. This forces compounding devices to adapt to complex batch sizes and handle high-value biologics with zero waste. This trajectory is highlighted by regulatory trends; according to the Personalized Medicine Coalition's May 2025 report, 'Personalized Medicine at FDA: The Scope & Significance of Progress in 2024,' the FDA approved 18 new personalized medicines in 2024, representing 38% of newly approved therapeutic molecular entities. Key Market Players * Baxter International Inc. * B. Braun SE. * COMECER S.p.A. * ARxIUM Inc. * Omnicell Inc. * Grifols, S.A. * Weibond Technology * Equashield LLC. * ICU Medical, Inc * NewIcon Oy Report Scope In this report, the Global Automated Compounding Device (Oncology) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: # Automated Compounding Device (Oncology) Market, By Technology * Gravimetric Compounding System * Volumetric Compounding System # Automated Compounding Device (Oncology) Market, By End User * Hospitals * Chemotherapy Centers * Others # Automated Compounding Device (Oncology) Market, By Region * North America United States Canada Mexico * Europe France United Kingdom Italy Germany Spain * Asia Pacific China India Japan Australia South Korea * South America Brazil Argentina Colombia * Middle East & Africa South Africa Saudi Arabia UAE Competitive Landscape Company Profiles: Detailed analysis of the major companies present in the Global Automated Compounding Device (Oncology) Market. Available Customizations: Global Automated Compounding Device (Oncology) Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: Company Information * Detailed analysis and profiling of additional market players (up to five).